Intellect Neurosciences Inc. (fka ILNS)

[James salmon]

Reason for new Phase 1 is because of below;

In 2011, we redirected the focus of the OX1 program from Alzheimer's disease to FA. Research suggests that the symptoms associated with FA are the result of oxidative stress caused by the abnormal accumulation of iron1,2. The Company recognized that OX1's ability to neutralize ROS could be an effective agent to reduce oxidative stress in FA, thereby eliminating the symptoms of FA and increasing both quality of life and longevity in affected individuals.


Because it was refocused from Alzheimer's to FA. Previous trials were conducted on healthy elderly patients, this trial is being conducted on people with FA.